Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Gains Access to Crucell Vaccine Tech | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merck Gains Access to Crucell Vaccine Tech

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck & Co., Inc. has exercised an option for the exclusive use of Crucell N.V.’s PER.C6 technology and an option for access to its AdVac vaccine technology in two infectious disease areas.

Dr. Jaap Goudsmit, Crucell’s chief scientific officer, said, “We are excited about this technology agreement which represents a further expansion of the relationship between our company and Merck. Crucell’s vaccine technologies, PER.C6 and AdVac, are increasingly used by the vaccine industry to develop important novel vaccines for infectious diseases. This agreement further broadens the number of disease areas in which our technologies are used.”

Under the terms of the agreement, Crucell acquires rights to certain cell-line technology developed by Merck for the manufacturing of recombinant proteins. The option and rights to technology developed by Merck are related to a cross-license agreement signed by the two companies in December 2006.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters